An observational study in Obesity and Overweight, sponsored by University Hospital Schleswig-Holstein. Terminated at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by University Hospital Schleswig-Holstein · Observational
This study aims to develop a simple, clinically applicable method for metabolic phenotyping to personalize obesity therapy in morbidly obese individuals. The underlying concept is that the way a person's resting metabolic rate (RMR) responds to a 24-hour fast can help distinguish between two metabolic phenotypes. Individuals with a "thrifty" metabolism show a significant drop in RMR during fasting, which may make them less responsive to conventional weight loss interventions. In contrast, those with a "spendthrift" metabolism exhibit little to no drop-or even a slight increase-in RMR, suggesting they may lose weight more readily.
The trial is designed as a prospective, single-center, longitudinal cohort study involving 20 morbidly obese patients (BMI >40 kg/m²) who are already participating in a multimodal obesity therapy program. The study is divided into three phases. In the baseline phase, participants undergo comprehensive screening, which includes physical examinations, blood tests, and body composition assessments. RMR is measured using indirect calorimetry both before and after a 24-hour fasting period, and a device (Lumen™) is used to assess whether the body is primarily burning carbohydrates or fats.
After the fasting measurements, participants perform a low-protein meal test by consuming a specially calibrated chocolate beverage. Their RMR is then monitored at several time points to determine the energy required for digestion. Following this, the study moves into the very-low-calorie diet (VLCD) phase, where participants consume approximately 800 kcal per day using formula meals tailored to meet their nutritional needs despite the calorie restriction. During this 12-week phase, changes in body weight, composition, and metabolic parameters are closely monitored.
The final phase of the study is a 12-week weight maintenance period, during which the focus is on sustaining the achieved weight loss. In addition to RMR and dietary assessments, advanced techniques such as metabolomics are employed. Blood, urine, and saliva samples are collected to analyze metabolic profiles and identify potential hormonal biomarkers-such as leptin, FGF21, and adrenaline-that could further differentiate the "thrifty" and "spendthrift" phenotypes. Body composition is also assessed using methods like bioimpedance analysis (BIA), quantitative magnetic resonance imaging (qMR), and air displacement plethysmography (BodPod).
By correlating the changes in RMR with metabolic and hormonal markers, the study tests the hypothesis that individuals with a marked RMR decrease during fasting (the "thrifty" phenotype) may experience less weight loss during a hypocaloric diet compared to those with minimal RMR change (the "spendthrift" phenotype). If validated, this approach could allow clinicians to predict weight loss outcomes more accurately and tailor obesity treatments to the individual's unique metabolic profile.
This study is a prospective, single-center, longitudinal cohort trial designed to unravel the metabolic heterogeneity among morbidly obese individuals and to develop a clinically feasible method for metabolic phenotyping. The aim is to identify distinct metabolic responses to a controlled fasting period that may predict weight loss outcomes and guide personalized obesity therapy.
Potential participants are morbidly obese patients (BMI >40 kg/m²) already enrolled in a multimodal obesity therapy program at the University Hospital Schleswig-Holstein, Campus Kiel. The screening process includes a thorough medical history, physical examination, and laboratory testing to exclude confounding conditions that might affect energy expenditure or the interpretation of metabolic measurements.
In the baseline phase, enrolled subjects undergo extensive assessments to characterize their metabolic status. Body composition is evaluated using several complementary techniques: bioimpedance analysis (BIA), quantitative magnetic resonance imaging (qMR), and air displacement plethysmography (BodPod). These methods provide detailed insights into fat mass, lean mass, and overall body composition. Resting metabolic rate (RMR) is measured using indirect calorimetry, with subjects placed under a canopy (haubenkalorimeter) that records oxygen consumption and carbon dioxide production to yield precise energy expenditure data.
A critical component of the study is the evaluation of RMR before and after an extended fasting period. Initially, RMR is measured following a 12-hour overnight fast. Participants then complete a 24-hour fasting period, during which continuous monitoring-via devices such as a continuous glucose monitor-ensures compliance with the fasting protocol. A second RMR measurement is taken after the fasting period, and the percentage change in RMR is calculated. Based on previous research, a significant RMR reduction (≥5.7%) classifies a subject as having a "thrifty" metabolic phenotype, while a minimal reduction or slight increase (≥+3.8%) indicates a "spendthrift" phenotype. Subjects with intermediate changes are not categorized for the primary analysis.
Following the fasting assessments, participants undergo a low-protein meal test. They consume a standardized chocolate beverage calibrated to provide 50% of their baseline RMR in caloric content. Postprandial RMR is then measured at several intervals over a three-hour period to assess the thermic effect of food and the energy cost associated with digestion. This test helps to elucidate differences in nutrient oxidation and metabolic flexibility between the two phenotypes.
After completing the baseline phase, subjects enter a 12-week very-low-calorie diet (VLCD) phase. During this period, they consume approximately 800 kcal per day through nutritionally complete formula meals that are designed to maintain a balanced macronutrient profile despite severe caloric restriction. Weight, body composition, and metabolic parameters are monitored on a weekly basis to capture the effects of the dietary intervention. The hypothesis is that individuals with a "thrifty" metabolic response may lose less weight compared to those with a "spendthrift" response, owing to their reduced energy expenditure during fasting.
Following the VLCD phase, patients transition into a 12-week weight maintenance phase. In this period, the focus shifts to sustaining weight loss and monitoring long-term metabolic changes. RMR, body composition, and dietary intake continue to be assessed periodically. Participants also use an activity tracker to document daily physical activity, ensuring that variations in energy expenditure are accounted for in the analysis.
An innovative aspect of this study is the incorporation of metabolomic analysis to identify potential biomarkers linked to the metabolic phenotypes. Biological samples-including blood, urine, and saliva-are collected at various time points throughout the study. These samples undergo metabolomic profiling using advanced techniques such as liquid chromatography-mass spectrometry (LC/MS) and nuclear magnetic resonance (NMR) spectroscopy. The goal is to identify specific metabolites or patterns-such as variations in leptin, fibroblast growth factor 21 (FGF21), and catecholamines-that correlate with the magnitude of RMR change during fasting. This analysis may reveal novel biomarkers that predict weight loss responsiveness and metabolic health.
Data collection extends beyond metabolic measurements. Participants complete visual analog scales (VAS) to assess subjective feelings of hunger and satiety, providing insights into the behavioral dimensions of appetite regulation. In addition, continuous glucose monitoring and measurements of beta-hydroxybutyrate levels are used to verify fasting compliance and to ensure the accuracy of the metabolic assessments.
The study is managed by a multidisciplinary team led by Dr. Tim Hollstein, with contributions from specialists in endocrinology, diabetology, clinical nutrition, and metabolomics. Collaborations with experts from associated institutions enhance the methodological rigor and analytical capacity of the trial. Statistical power calculations, based on prior studies, indicate that approximately 20 subjects (10 per extreme phenotype group) are required to detect significant differences in weight loss outcomes. To accommodate variability and potential dropouts, an initial screening of around 80 individuals is planned.
Safety and compliance are paramount. The protocol includes rigorous monitoring for adverse events related to fasting, blood sampling, and the use of continuous monitoring devices. Subjects who do not meet fasting criteria-confirmed via continuous glucose readings or ketone measurements-are excluded from the primary analysis but continue to receive standard obesity therapy.
Ultimately, the study seeks to bridge the gap between complex laboratory-based measurements and practical clinical applications. By establishing a reliable and straightforward method for metabolic phenotyping, it aims to enable personalized obesity treatments that are tailored to an individual's unique metabolic profile. This approach could revolutionize obesity management by providing clinicians with predictive tools to optimize weight loss interventions and improve long-term metabolic outcomes.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's enrollment of 35 is below the median of 114 across 2,154 observational studies indexed under Obesity.
Browse Obesity studies →University Hospital Schleswig-Holstein is the lead sponsor of 163 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of adult men and women (ages 18 to 70) with a body mass index (BMI) above 40 kg/m² who are receiving care at the Department of Internal Medicine I at the University Hospital Schleswig-Holstein (UKSH), Campus Kiel. All participants are enrolled in a multimodal obesity therapy program that includes nutritional counseling, behavioral interventions, and exercise components. Eligible individuals must meet the specified inclusion criteria and have no conditions that could confound study results or compromise patient safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals with a fasting-induced decrease of RMR \< -5.7%
Individuals with a fasting-induced increase of RMR \> +3.8%
Individuals with fasting-induced RMR changes greater than -5.7% and lower than +3.8%
Change in Resting Metabolic Rate (RMR) From Baseline to 24 Hours After Fasting
RMR (measured in kcal/day) is assessed via indirect calorimetry at baseline (after an overnight fast) and again following a 24-hour fasting period. The primary metric is the absolute change in RMR (kcal/day) or percentage change from baseline. Participants who experience a significant RMR decrease ("thrifty" phenotype) are hypothesized to lose less weight during a subsequent hypocaloric diet than those with a minimal or increased RMR ("spendthrift" phenotype).
Time frame: Baseline to Week 12
Change in Plasma FGF21 From Baseline to 24 Hours After Fasting
Fibroblast growth factor 21 (FGF21) is measured in plasma (e.g., pg/mL) at baseline (after an overnight fast) and again after 24 hours of fasting. The difference in FGF21 concentrations serves as a potential biomarker for the thrifty phenotype, correlating with a significant RMR drop. Higher FGF21 changes may indicate greater metabolic adaptation to fasting.
Time frame: Baseline, after 24-hour fast, and throughout the 6-month study period (up to Week 26)
Meal-Induced Thermogenesis as a Predictor of Weight and Fat Mass Loss
Assesses whether the thermic effect of a standardized low-protein meal (meal-induced thermogenesis, MIT) can predict subsequent weight and fat mass changes. MIT is measured via indirect calorimetry at baseline after a 24-hour fast, and these data are correlated with weight and body composition outcomes during the 12-week very-low-calorie diet (VLCD) and the following 12-week weight maintenance phase.
Time frame: Day 1 (immediately following 24-hour fast) for the low-protein meal test, with follow-up assessments at Week 12 (end of VLCD) and Week 26 (end of weight maintenance).
Metabolic Flexibility (Respiratory Quotient Changes)
Assesses whether "thrifty" individuals (significant RMR drop) show reduced metabolic flexibility, defined by a smaller change in respiratory quotient (RQ) after the 24-hour fast and after a low-protein meal challenge.
Time frame: Baseline (Day 0), after 24-hour fast (Day 1), and during the low-protein meal test (Day 1)
Subjective Hunger After 24-Hour Fast
Evaluates whether participants with a significant RMR drop ("thrifty" phenotype) report greater hunger following a 24-hour fasting period compared to those with minimal or increased RMR. Hunger is measured using visual analog scales (VAS) at baseline and immediately after the fast.
Time frame: Baseline (Day 0) and after 24-hour fast (Day 1)
Changes in Fat Mass During and After a Hypocaloric Diet
Determines whether "thrifty" individuals lose less fat mass during a 12-week very-low-calorie diet (VLCD) and whether they regain weight and fat mass more rapidly in the subsequent 12-week weight maintenance phase compared to "spendthrift" individuals. Body composition is measured via bioimpedance, BodPod, and qMR.
Time frame: Baseline, Week 12 (end of VLCD), and Week 26 (end of maintenance phase)
Gut Microbiome Differences
Explores whether the gut microbiome composition differs between thrifty and spendthrift individuals at baseline and whether these differences persist or change following the VLCD and maintenance phases. Stool samples are collected for microbiome analysis.
Time frame: Baseline, Week 12, and Week 26
Thermogenic and Appetite-Regulating Hormone Composite Index
A composite index derived from standardized concentrations of leptin, FGF21, free T3 (FT3), free T4 (FT4), growth hormone (GH), adiponectin, ghrelin, GLP-1, secretin, and insulin. Each hormone is measured in its relevant unit (e.g., pg/mL, ng/mL) at baseline, after a 24-hour fast, and at Weeks 12 and 26. The data are converted into z-scores and averaged to create a single composite value, where higher scores indicate higher overall hormone levels. This index is used to compare changes in thermogenic and appetite-regulating hormone activity between "thrifty" and "spendthrift" metabolic phenotypes over time.
Time frame: Baseline, after 24-hour fast (Day 1), Week 12, and Week 26
Long-Term Change in Metabolic Phenotype
Evaluates whether the metabolic phenotype (thrifty vs. spendthrift) remains stable or changes following the 12-week VLCD and 12-week weight maintenance period. RMR is measured again at the end of the study to detect any persistent or altered metabolic adaptations.
Time frame: Baseline, Week 12, and Week 26
Association of RMR Changes With Meal-Induced Thermogenesis
Investigates the correlation between the magnitude of RMR change after fasting and the thermic effect of a low-protein meal. Postprandial energy expenditure is measured via indirect calorimetry at multiple time points following meal ingestion.
Time frame: Baseline (Day 0) and during low-protein meal test (Day 1)
Association Between CO₂ Production and Energy Expenditure
Pearson's correlation coefficient (dimensionless) is calculated between CO₂ production (e.g., mL/min) measured by a handheld device (Lumen™) and energy expenditure (kcal/day) measured by indirect calorimetry. Measurements are taken at baseline, after a 24-hour fast, and during the postprandial phase of a low-protein meal test. A higher positive coefficient indicates a stronger association between CO₂ production and total energy expenditure.
Time frame: Baseline (Day 0), after 24-hour fast (Day 1), and throughout the 6-month study period
Correlation Between Resting Metabolic Rate and Respiratory Quotient
Pearson's correlation coefficient (dimensionless) is calculated between resting metabolic rate (kcal/day) and respiratory quotient (unitless) measured at baseline, after a 24-hour fast, and during subsequent diet phases (up to Week 26). A higher positive correlation indicates a stronger link between RMR and RQ changes
Time frame: Baseline (Day 0), after 24-hour fast (Day 1), and during subsequent diet phases (up to Week 26)
Correlation Between Diet-Induced Thermogenesis (DIT) and Postprandial FGF21 Levels
Pearson's correlation coefficient (dimensionless) is calculated between DIT (measured in kcal or kcal/day) and FGF21 concentrations (measured in pg/mL) at baseline, after a 24-hour fast, and during a low-protein meal test. A higher positive correlation indicates a stronger relationship between the magnitude of meal-induced thermogenesis and postprandial FGF21 secretion.
Time frame: During the low-protein meal test (Day 1) and optionally at subsequent time points (Week 12, Week 26)
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Mar 2026, 29 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Schleswig-Holstein →